ArticleReviews in cardiovascular medicine2025
Coronary Computed Tomography Angiography Atherosclerotic Plaque Volume as A Predictor of Myocardial Blood Flow Impairment in Non-Obstructive Coronary Artery Disease.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pericoronary Adipose Tissue Radiomic Features and Quantitative Plaque Analysis in Coronary Artery Disease: Insights from Coronary Computed Tomography Angiography.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Studies have demonstrated that patients with non-obstructive coronary artery disease (NOCAD) have an increased risk of myocardial infarction and all-cause mortality, particularly due to coronary microvascular dysfunction (CMD). Moreover, the features of atherosclerotic plaque can affect myocardial blood flow (MBF); however, data on these findings remain limited. Therefore, this study aimed to assess the impact of quantitative coronary computed tomography angiography (CCTA)-derived atherosclerotic plaque features on myocardial perfusion and MBF in NOCAD patients measured using dynamic cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT). Methods: Based on the CCTA results, a total of 49 NOCAD patients (stenosis <50%, 29 men, mean age 57.4 ± 9.0 years) were included in the study. In addition to estimating stenosis severity, the plaque volume (mm Results: Based on the MFR values, patients were divided into two groups: Group 1 consisted of patients with reduced MFR (<2.0, n = 20), and Group 2 consisted of those with normal MFR (≥2.0, n = 29). Not all patients had severe myocardial perfusion abnormalities, as determined by standard myocardial perfusion imaging indexes. Analysis of the CCTA data demonstrated that small volumes and burdens of atherosclerotic plaques were characteristic of patients. Stress was significantly correlated with total plaque volume (Spearman's rank correlation coefficient (ρ) = -0.402) and burden (ρ = -0.374), as well as non-calcified plaque volume (ρ = -0.341) and burden (ρ = -0.314). Rest significantly correlated with total plaque volume (ρ = -0.504) and burden (ρ = -0.432), and non-calcified plaque volume (ρ = -0.471) and burden (ρ = -0.433). Meanwhile, MFR and standard indexes of myocardial perfusion impairment did not exhibit significant associations with quantitative CCTA parameters. Multivariate logistic regression analysis revealed that only total plaque volume (odds ratio 1.01; 95% confidence interval 1.005-1.030; Conclusions: Total plaque volume, derived from quantitative CCTA data, represents an independent predictor of reduced stress-related MBF of less than 1.5 mL/min/g, as obtained using dynamic CZT-SPECT, even in the absence of obstructive coronary artery disease (CAD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.